The latest update is out from Foghorn Therapeutics ( (FHTX) ).
Foghorn Therapeutics is making strides in oncology with its Gene Traffic Control Platform, evidenced by the recent dosing of its first patient with the SMARCA2 inhibitor FHD-909 in Phase 1 trials focused on NSCLC. The company anticipates key data from its AML study with FHD-286 by year-end and plans to kickstart IND-enabling studies for its CBP degrader program. With a robust financial position of $267.4 million, Foghorn is well-equipped to advance its pipeline into 2027, aiming to transform treatments for a variety of cancers.
See more insights into FHTX stock on TipRanks’ Stock Analysis page.
